The present study strengthens the evidence that FcγR polymorphisms and haplotypes influence the clinical and serological subgroup of GBS, as well as the strength of the immune responses that ultimately trigger the development of GBS and affect disease severity. The gene discussed is FCGR2A; the disease is Guillain-Barre syndrome.